Lv31
350 积分 2025-07-10 加入
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
9小时前
待确认
Practical and Scalable Method for Manufacturing AZD4604, A Potent and Selective JAK1 Inhibitor
1个月前
已完结
First Multikilogram Synthesis of the Next-Generation Oral Selective ERα Degrader Camizestrant
1个月前
已完结
Abstract 1718: Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index
1个月前
已关闭
Ramping up the express stairs: Lisaftoclax in CLL
2个月前
已完结
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
2个月前
已完结
Lisaftoclax: First Approval
2个月前
已完结
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2个月前
已完结
Mechanisms of BCL-2 family proteins in mitochondrial apoptosis
2个月前
已完结
[Physiological Function and Structural Basis of Bcl-2 Family Proteins]
2个月前
已关闭
皖公网安备34019202002308
